Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
Arora SP, Tenner L, Sarantopoulos J, Morris J, Liu Q, Mendez JA, Curiel T, Michalek J, Mahalingam D. Arora SP, et al. Among authors: mahalingam d. Br J Cancer. 2022 Oct;127(6):1153-1161. doi: 10.1038/s41416-022-01892-6. Epub 2022 Jun 23. Br J Cancer. 2022. PMID: 35739299 Free PMC article. Clinical Trial.
Targeting HSP90 for cancer therapy.
Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Mahalingam D, et al. Br J Cancer. 2009 May 19;100(10):1523-9. doi: 10.1038/sj.bjc.6605066. Epub 2009 Apr 28. Br J Cancer. 2009. PMID: 19401686 Free PMC article. Review.
The Pim kinases: new targets for drug development.
Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. Swords R, et al. Among authors: mahalingam d. Curr Drug Targets. 2011 Dec;12(14):2059-66. doi: 10.2174/138945011798829447. Curr Drug Targets. 2011. PMID: 21777193 Review.
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. Rosen LS, et al. Among authors: mahalingam d. Clin Cancer Res. 2012 Jun 15;18(12):3414-27. doi: 10.1158/1078-0432.CCR-11-3369. Epub 2012 Apr 17. Clin Cancer Res. 2012. PMID: 22510349 Clinical Trial.
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. Rodon J, et al. Among authors: mahalingam d. Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12. Clin Cancer Res. 2014. PMID: 24523439 Free article. Clinical Trial.
114 results